Trial reportNature communications2017
Tumor-associated B-cells induce tumor heterogeneity and therapy resistance.
Open access · goldAbstract readClinical Trial, Phase II
In one paragraph
Trial report in Nature communications, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 94 papers.
0numbers the graph read from it
0cells of the map it votes in
94citing papers in PubMed
6.5field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
94 citing papers in PubMed, 139 citations in OpenAlex.
- Liver-directed treatment is associated with improved survival and increased response to immune checkpoint blockade in metastatic uveal melanoma: results from a retrospective multicenter trial.Frontiers of medicine · 2023Trial
- Baseline circulating unswitched memory B cells and B-cell related soluble factors are associated with overall survival in patients with clear cell renal cell carcinoma treated with nivolumab within the NIVOREN GETUG-AFU 26 study.Journal for immunotherapy of cancer · 2022Trial
- B cells and humoral immunity in melanoma: regulatory and autoimmune-like features and implications for immunotherapy.Oncoimmunology · 2026Review
- B cells in cancer: functions, mechanisms and therapeutic advances.Signal transduction and targeted therapy · 2026Review
- Cancer stem cell plasticity: mechanisms, immune microenvironment crosstalk, and therapeutic implications.Journal of hematology & oncology · 2026Review
- Advances and prospects in cell therapy for cancer: explorations from T cells to stem cells.Signal transduction and targeted therapy · 2026Review
- Phenotypic, functional, prognostic and predictive significance of B-cell and antibody responses in human melanoma: a scoping review.The British journal of dermatology · 2026Article
- Uncovering the Intricate and Heterogeneous Cellular Microenvironment of Cutaneous Melanoma.Medicina (Kaunas, Lithuania) · 2026Review
- Article
- The Role of B Cells in Tumorigenesis and Immunotherapy.Immune network · 2026Review
- Spatial Profiling and Prognostic Role of Tumor-Infiltrating CD8+ T and CD20+ B Cells in Metastatic Clear Cell Renal Cell Carcinoma Treated with Sequential Tyrosine Kinase Inhibitors and Nivolumab.Journal of Cancer · 2026Article
- Targeting tumour-infiltrating B cells: mechanisms and advances in cancer therapy.Cell death & disease · 2025Review
- In-depth patient-specific analysis of tumor heterogeneity in melanoma brain metastasis: Insights from spatial transcriptomics and multi-region bulk sequencing.Translational oncology · 2025Article
- The role of regulatory B cell/T follicular helper cell balance in thymoma and thymoma-associated myasthenia gravis.Scientific reports · 2025Article
- Masters of adaptation: How cancer and immune cell plasticity mediates tumor progression.PLoS biology · 2025Review
- Multifaceted function of B cells in tumorigenesis.Frontiers of medicine · 2025Review
- Article
- Fibroblast growth factor receptor alterations and resistance mechanisms in the treatment of pediatric solid tumors.Cancer drug resistance (Alhambra, Calif.) · 2025Article
- Advancements and Challenges in Personalized Therapy forJournal of clinical medicine · 2024Review
- Article
34 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
53 authors at 15 institutions in 4 countries.
Rajasekharan SomasundaramThe Wistar Institute, Philadelphia, PA, 19104, USA. Shyam@wistar.org.
Gao ZhangThe Wistar Institute, Philadelphia, PA, 19104, USA.
Mizuho Fukunaga-KalabisThe Wistar Institute, Philadelphia, PA, 19104, USA.
Michela PeregoThe Wistar Institute, Philadelphia, PA, 19104, USA.
Clemens KreplerThe Wistar Institute, Philadelphia, PA, 19104, USA.
Xiaowei XuDepartment of Pathology and Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Christine WagnerDivision of Immunology, Allergy and Infectious Diseases (DIAID), Department of Dermatology, Medical University of Vienna, Vienna, A-1090, Austria.
Denitsa HristovaThe Wistar Institute, Philadelphia, PA, 19104, USA.
Jie ZhangNew Jersey Institute of Technology, Newark, NJ, 07102, USA.ORCID http://orcid.org/0000-0003-0242-8812
Tian TianNew Jersey Institute of Technology, Newark, NJ, 07102, USA.
Zhi WeiNew Jersey Institute of Technology, Newark, NJ, 07102, USA.
Qin LiuThe Wistar Institute, Philadelphia, PA, 19104, USA.ORCID http://orcid.org/0000-0001-9964-580X
Kanika GargDivision of Immunology, Allergy and Infectious Diseases (DIAID), Department of Dermatology, Medical University of Vienna, Vienna, A-1090, Austria.
Johannes GrissDivision of Immunology, Allergy and Infectious Diseases (DIAID), Department of Dermatology, Medical University of Vienna, Vienna, A-1090, Austria.
Rufus HardsThe Wistar Institute, Philadelphia, PA, 19104, USA.
Margarita MaurerDivision of Immunology, Allergy and Infectious Diseases (DIAID), Department of Dermatology, Medical University of Vienna, Vienna, A-1090, Austria.
Christine HafnerDepartment of Dermatology and Venereology, Karl Landsteiner University of Health Sciences, St. Pölten, A-3100, Austria.
Marius MayerhöferDepartment of Radiology, Division of Nuclear Medicine, Medical University of Vienna, Vienna, A-1090, Austria.
Georgios KaranikasDepartment of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, A-1090, Austria.
Ahmad JaliliDivision of Immunology, Allergy and Infectious Diseases (DIAID), Department of Dermatology, Medical University of Vienna, Vienna, A-1090, Austria.
Verena Bauer-PohlDivision of Immunology, Allergy and Infectious Diseases (DIAID), Department of Dermatology, Medical University of Vienna, Vienna, A-1090, Austria.
Felix WeihsengruberDepartment of Dermatology and Venereology, The Rudolfstiftung Hospital, Teaching Hospital of the Medical University Vienna, Vienna, A-1030, Austria.
Klemens RappersbergerDepartment of Dermatology and Venereology, The Rudolfstiftung Hospital, Teaching Hospital of the Medical University Vienna, Vienna, A-1030, Austria.
Josef KollerDepartment of Dermatology, Paracelsus Medical University Salzburg, Salzburg, A-5020, Austria.
Roland LangDepartment of Dermatology, Paracelsus Medical University Salzburg, Salzburg, A-5020, Austria.
Courtney HudgensDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77040, USA.ORCID http://orcid.org/0000-0001-8312-7485
Guo ChenDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77040, USA.
Michael TetzlaffDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77040, USA.
Lawrence WuThe Wistar Institute, Philadelphia, PA, 19104, USA.
Dennie Tompers FrederickMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, 02115, USA.
Richard A ScolyerMelanoma Institute of Australia, and The University of Sydney, Sydney, 2065, Australia.
Georgina V LongMelanoma Institute of Australia, and The University of Sydney, Sydney, 2065, Australia.
Manashree DamleThe Wistar Institute, Philadelphia, PA, 19104, USA.
Courtney EllingsworthThe Wistar Institute, Philadelphia, PA, 19104, USA.
Leon GrinmanThe Wistar Institute, Philadelphia, PA, 19104, USA.
Harry ChoiThe Wistar Institute, Philadelphia, PA, 19104, USA.
Brian J GavinThe Wistar Institute, Philadelphia, PA, 19104, USA.
Margaret DunaginDepartment of Bioengineering, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Arjun RajDepartment of Bioengineering, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Nathalie SchollerAbramson Cancer Center, Hospital of University of Pennsylvania, Philadelphia, PA, 19104, USA.
Laura GrossThe Wistar Institute, Philadelphia, PA, 19104, USA.
Marilda BeqiriThe Wistar Institute, Philadelphia, PA, 19104, USA.
Keiryn BennettCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, A-1090, Austria.ORCID http://orcid.org/0000-0001-9356-7708
Ian WatsonDepartment of Biochemistry, McGill University, Montreal, QC, Canada, H3A0G4.
Helmut SchaiderDermatology Research Center, University of Queensland Diamantina Institute, The University of Queensland, Translational Research Institute, Brisbane, 4102, Australia.
Michael A DaviesDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77040, USA.
Jennifer WargoDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer, Center, Houston, TX, 77040, USA.
Brian J CzernieckiAbramson Cancer Center, Hospital of University of Pennsylvania, Philadelphia, PA, 19104, USA.
Lynn SchuchterAbramson Cancer Center, Hospital of University of Pennsylvania, Philadelphia, PA, 19104, USA.
Dorothee HerlynThe Wistar Institute, Philadelphia, PA, 19104, USA.
Keith FlahertyMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, 02115, USA.
Meenhard HerlynThe Wistar Institute, Philadelphia, PA, 19104, USA. Herlynm@wistar.org.
Stephan N WagnerDivision of Immunology, Allergy and Infectious Diseases (DIAID), Department of Dermatology, Medical University of Vienna, Vienna, A-1090, Austria. stephan.wagner@meduniwien.ac.at.ORCID http://orcid.org/0000-0003-4941-7029
The Wistar Institute · USMedical University of Vienna · ATThe University of Texas MD Anderson Cancer Center · USNew Jersey Institute of Technology · USUniversity of Pennsylvania · USHarvard University · USHospital of the University of Pennsylvania · USParacelsus Medical University · ATRudolfinerhaus Hospital · ATThe University of Sydney · AUAustrian Academy of Sciences · ATKarl Landsteiner University of Health Sciences · ATMcGill University · CASRI International · USTranslational Research Institute · AU
Funding
Tumor Microenvironment and MetastasisP30CA010815 · NCI · WISTAR INSTITUTE · PI Luis J Montaner · 1985 to 2026
$75.9MTargeting the MAP and PI3 Kinase Pathways in MelanomaP01CA114046 · NCI · WISTAR INSTITUTE · PI MURPHY, MAUREEN E. · 2008 to 2023
$37.1MTUMOR DEVELOPMENT AND PROGRESSION IN HUMAN MELANOCYTESP01CA025874 · NCI · WISTAR INSTITUTE · PI MARMORSTEIN, RONEN · 1985 to 2015
$19.0MTargeted Combination Therapy for MelanomaP50CA174523 · NCI · WISTAR INSTITUTE · PI HERLYN, MEENHARD F · 2014 to 2018
$11.1MMETASTATIS: BIOLOGICAL PHENOTYPE AND MODELS FOR THERAPYR01CA047159 · NCI · WISTAR INSTITUTE · PI HERLYN, MEENHARD F · 1989 to 2015
$3.9MNCI NIH HHS P01 CA025874NCI NIH HHS P01 CA114046NCI NIH HHS P30 CA010815NCI NIH HHS P50 CA174523NCI NIH HHS R01 CA047159
Abstract
In melanoma, therapies with inhibitors to oncogenic BRAF
Indexed as
Drug Resistance, NeoplasmAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsB-LymphocytesCell SurvivalCisplatinFibroblast Growth Factor 2HumansInsulin-Like Growth Factor IIn Vitro TechniquesLymphocytes, Tumor-InfiltratingMelanomaPaclitaxelPilot ProjectsProtein Kinase InhibitorsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsBRAF protein, humanCisplatinFGFR3 protein, humanFibroblast Growth Factor 2IGF1 protein, humanInsulin-Like Growth Factor IofatumumabPaclitaxelProtein Kinase InhibitorsProto-Oncogene Proteins B-rafReceptor, Fibroblast Growth Factor, Type 3
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.